GL
ACHN

GLG LLC’s Achillion Pharmaceuticals ACHN Stock Holding History

GLG LLC’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-50,000
Closed -$346K – 613
2015
Q3 		$346K Sell
50,000
-104,832
-68% -$854K 0.01% 517
2015
Q2 		$1.37M Buy
+154,832
New +$1.46M 0.03% 415

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GLG LLC's ACHN Position: Q4 2015 in Review

GLG LLC sold out of Achillion Pharmaceuticals (ACHN) in Q4 2015, closing a stake of 50,000 shares — an estimated $346K sold.

GLG LLC first reported a position in ACHN in Q2 2015 and held it in 2 quarters. The position peaked at $1.37M in Q2 2015. 152 funds tracked by Wall St. Rank hold ACHN as of Q4 2015.

  • GLG LLC reported no remaining Achillion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • GLG LLC sold 50,000 Achillion Pharmaceuticals shares in Q4 2015, an estimated $346K.
  • GLG LLC first reported a position in Achillion Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • GLG LLC's Achillion Pharmaceuticals position peaked at $1.37M in Q2 2015.
  • 152 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2015.

Based on GLG LLC's 13F filing for Q4 2015, filed 16 Feb 2016.